NEUMORA THERAPEUTICS, INC. Interest Expense Nonoperating
NEUMORA THERAPEUTICS, INC. (NMRA) reported Interest Expense Nonoperating of $1.82 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $1.82M, a 317.43% increase year-over-year.
- NEUMORA THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $1.85M.
- NEUMORA THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $2.04M.
- NEUMORA THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $747.00K.
- NEUMORA THERAPEUTICS, INC. interest expense nonoperating for fiscal 2025 was $3.22M.
- NEUMORA THERAPEUTICS, INC. interest expense nonoperating for fiscal 2024 was $0.00.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.82M 10-Q · filed 2026-08-14 | $3.67M 10-Q · filed 2026-08-14 | $5.71M derived: sum of 3 quarters · filed 2026-08-14 | $6.46M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.85M 10-Q · filed 2026-05-07 | $3.89M derived: sum of 2 quarters · filed 2026-05-07 | $4.64M derived: sum of 3 quarters · filed 2026-05-07 | $5.07M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.78M derived: sum of 2 quarters · filed 2026-03-30 | $3.22M derived: sum of 3 quarters · filed 2026-08-14 | $3.22M 10-K · filed 2026-03-30 |
| 2025-09-30 | $747.00K 10-Q · filed 2025-11-06 | $1.18M derived: sum of 2 quarters · filed 2026-08-14 | $1.18M 10-Q · filed 2025-11-06 | $1.18M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $436.00K 10-Q · filed 2026-08-14 | $436.00K 10-Q · filed 2026-08-14 | $436.00K derived: sum of 3 quarters · filed 2026-08-14 | $436.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $0.00 10-K · filed 2026-03-30 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |